GlassScriptPhysician profile
Halyna Mylko
NPI 1083045736
$4,917.99
in general payments reported to CMS, 2019-2025
30 companies · $862 in 2025
The $862 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $614 · 2020: $270 · 2021: $658 · 2022: $442 · 2023: $938 · 2024: $1,135 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,934.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $834.88 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $628.16 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $555.99 | 2019-2025 | Lifevest |
| Abbvie INC. | $447.23 | 2023-2025 | |
| Pfizer INC. | $367.75 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $353.88 | 2019-2024 | Eliquis |
| Neurelis, INC. | $300.00 | 2023-2024 | Valtoco |
| Kestra Medical Technology Services, INC. | $216.56 | 2024-2025 | Assure Wcd |
| Merck Sharp & Dohme LLC | $200.38 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Vanda Pharmaceuticals INC. | $119.86 | 2024 | Fanapt |
| Sk Life Science, INC. | $116.44 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $104.77 | 2019-2024 | Breztri, Airsupra |
| Janssen Biotech, INC. | $88.28 | 2019-2020 | |
| Tesaro, INC. | $68.22 | 2019 | |
| Amgen INC. | $67.51 | 2021-2025 | Otezla, Repatha |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $54.81 | 2019-2021 | |
| Viiv Healthcare Company | $48.49 | 2023 | Apretude, Cabenuva |
| Puma Biotechnology, INC. | $44.64 | 2019 | |
| Global Blood Therapeutics, INC. | $44.04 | 2021 | |
| Abbott Laboratories | $31.42 | 2025 | Cardiomems |
| Eisai INC. | $28.46 | 2025 | |
| Opko Pharmaceuticals, LLC | $28.01 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $24.63 | 2019 | |
| Shield Therapeutics INC | $23.33 | 2025 | |
| Alnylam Pharmaceuticals INC. | $22.68 | 2023 | Amvuttra |
| Alexion Pharmaceuticals, INC. | $22.11 | 2019 | |
| Philips North America LLC | $21.56 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.92 | 2019 | |
| Biogen, INC. | $19.62 | 2025 | Leqembi |
| Janssen Scientific Affairs, LLC | $14.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Halyna Mylko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.